Jennifer J. Rhodes, who serves as Executive Vice President, Chief Legal Officer and Secretary at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), reported the sale of 3,844 shares of company common stock on March 25, 2026. The shares changed hands at $21.47 apiece, generating proceeds of $82,530, according to a Form 4 filing with the Securities and Exchange Commission.
The filing also records that Rhodes exercised options to acquire 7,515 shares of Acadia common stock on March 24, 2026, at an exercise price of $0. After completing the exercise and subsequent sale, Rhodes is listed as directly owning 11,280 shares of Acadia.
Market metrics included in the filing and related data note that Acadia carries a market valuation of $3.67 billion, trades at a price-to-earnings ratio of 9.4, and is assigned a "GREAT" financial health score. The company is cited as trading below its InvestingPro Fair Value, a point that the filing highlights as an indication the stock may be undervalued at current levels.
Separately, regulatory and analyst developments have added context to Acadia’s recent trading backdrop. The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a negative opinion on Acadia’s Marketing Authorization Application for trofinetide, the company’s treatment candidate for Rett syndrome. The committee expressed concern about the limited magnitude of the treatment effect and noted that the study did not capture all core symptoms.
On the analyst front, BofA Securities initially reduced its price target on Acadia to $29 from $31 while maintaining a Neutral rating, a move the firm said followed a review of the company’s pipeline and the regulatory outcome in the EU. BofA subsequently upgraded Acadia’s stock rating to Buy from Neutral, citing valuation as the driver of the change rather than any revision to the company’s underlying fundamentals.
Corporate governance activity also appeared in recent disclosures. Acadia appointed Jonathan M. Poole to its board of directors and to the audit committee. Mr. Poole will serve as a Class II director, with his initial term set to expire at the 2027 annual meeting of stockholders.
Taken together, the insider transaction, the EMA committee opinion, analyst target and rating adjustments, and the board appointment illustrate a period of active developments for Acadia Pharmaceuticals.